CHICAGO and PUNE, India, July 2, 2025 /PRNewswire/ --
What's Behind the Surge in the US$3.22 Billion Feed Phosphate Market?
The Feed Phosphate Market is projected to be...
Community Resource Rally Delivers Essential Aid to Local Families Facing Summer Insecurity
ROGERS, Ark., June 27, 2025 /PRNewswire/ -- With summer in full swing and...
Ah, the circus of fiscal responsibility, where politicians pretend to care about budget deficits only when it’s someone else's pet projects on the chopping...
Global Outdoor Enthusiast Dylan Efron, U.S. Open Champion Sloane Stephens, and More Join StarKist to Celebrate an Active, On-the-Go Lifestyle Powered by Ready-to-Eat Protein
RESTON, Va.,...
The lineup also includes a variety of new crab-centric dishes and festival-inspired drinks
ORLANDO, Fla., June 23, 2025 /PRNewswire/ -- Red Lobster is making a...
The annual general meeting of Icelandic Salmon AS (the "Company") was held on 18 June 2025 at 11:00 (CEST). All resolutions were approved as proposed by the board.
NICE, France, June 13, 2025 /CNW/ - Canada's oceans are facing increasing impacts from climate change, including species decline, biodiversity loss, ecosystem degradation, harm...
AKVA group ASA (“AKVA”) today hosts a Capital Markets Day where it introduces a revenue target of NOK 5 billion and an EBIT target of 9% for 2027 and outlines its ambitions for continued profitable growth to NOK 7 billion in 2030.
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology’s annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizumab pegol is ongoing with the goal of confirming the results from PHOENYCS GO.
/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/
Concurrent Non-brokered Private Placement Equity Financing of up to $2.25 Million Supported by Strategic Investor Michael Gentile
VANCOUVER,...
Hundreds of Families Receive Food and Household Essentials at Resource Rally
RESTON, Va., June 6, 2025 /PRNewswire/ -- Hunger remains a significant issue in communities throughout...